MedTrace Logo

Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation

NCT02028650 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-07-13

No results posted yet for this study

Summary

The relapse leukemia patients after transplantation were divided into two groups randomly. Group D1: patients received first-donor stem cells infusion(DSI) treatment with or without chemotherapy; group D2: patients received second-donor DSI treatment with or without chemotherapy. The second donors were preferably donors who were genetically related and had more HLA-match locus. The re-induction chemotherapy regimen was primarily MAT(mitoxantrone, cytarabine, Teniposide ) for acute myeloid leukemia (AML) and VMCLD(vincristine, Teniposide, cyclophosphamide, L-Asparaginase, Dexamethasone) for acute lymphocytic leukemia (ALL), and no graft versus host disease(GVHD) prevention was conducted pre- and post- therapy.

Conditions

  • Relapse Leukemia

Interventions

BIOLOGICAL

the first donor's stem cell

HLA-matched stem cell infusion

BIOLOGICAL

the second donor's stem cell

HLA-mismatched, the second donor's stem cell infusion

Sponsors & Collaborators

  • huishengai

    lead OTHER

Principal Investigators

  • qiao jianhui, MD · Affiliated Hospital of Academy of Military Medical Sciences

Eligibility

Min Age
9 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2013-02-28
Completion
2014-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02028650 on ClinicalTrials.gov